Form 4: Syros Pharmaceuticals Director Deborah Dunsire Reports Stock Transactions
SEC Form 4 Filing
Director Deborah Dunsire reports acquisition of 4,000 shares of Syros Pharmaceuticals common stock upon vesting of restricted stock units.
Summary
- On June 1, 2024, Deborah Dunsire, a director of Syros Pharmaceuticals, acquired 4,000 shares of common stock.
- The acquisition resulted from the vesting of restricted stock units (RSUs).
- Following the transaction, Dunsire directly owns 12,000 shares of Syros Pharmaceuticals common stock.
- The RSUs vested in their entirety on the first anniversary of the grant date.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing a stock transaction related to executive compensation. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC for insiders of publicly traded companies, providing transparency into their trading activities. This filing indicates routine compensation-related stock vesting for a Syros Pharmaceuticals director.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the increase in outstanding shares, but it is unlikely to be significant.
Key Dates
| Date | Description |
|---|---|
| 06/01/2024 | Date of transaction: Acquisition of 4,000 shares of common stock through RSU vesting. |
| 06/04/2024 | Date of signature on the Form 4 filing. |
Keywords
Syros Pharmaceuticals, Deborah Dunsire, Form 4, Stock Transaction, Restricted Stock Units, Director, SYRS, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.